CLINICAL_TRIALS ClinicalTrials.gov record with results posted

A Phase II, Randomized, Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics (PK) of Maintenance Cabozantinib (XL184) Plus Best Supportive Care (BSC) Versus BSC in Children, Adolescents and Young Adults (AYA) With Unresectable Residual Osteosarcoma Either at Diagnosis or at First Relapse After Standard Treatment

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06341712
Title field or adapter rule: {'original_value': 'A Phase II, Randomized, Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics (PK) of Maintenance Cabozantinib (XL184) Plus Best Supportive Care (BSC) Versus BSC in Children, Adolescents and Young Adults (AYA) With Unresectable Residual Osteosarcoma Either at Diagnosis or at First Relapse After Standard Treatment', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-30T01:05:27.967245+00:00
Published At: 2026-10-29T00:00:00+00:00
Record Updated At: 2026-10-29
Results Posted At: 2026-10-29
Source Retrieved At: 2026-10-30T01:05:26.713790+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

protocolSection.conditionsModule.conditions: ["Osteosarcoma", "Osteosarcoma in Children", "Osteosarcoma in Adolescents and Young Adults"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-29", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT06341712"
protocolSection.identificationModule.officialTitle: "A Phase II, Randomized, Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics (PK) of Maintenance Cabozantinib (XL184) Plus Best Supportive Care (BSC) Versus BSC in Children, Adolescents and Young Adults (AYA) With Unresectable Residual Osteosarcoma Either at Diagnosis or at First Relapse After Standard Treatment"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: {"date": "2026-10-29", "type": "ACTUAL"}

{'armGroupLabels': ['Arm A: Cabozantinib+ Best supportive care (BSC)'], 'description': 'Participants will receive cabozantinib orally Once daily (QD) on a continuous dosing schedule for cycles of 28 days.', 'name': 'Cabozantinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Arm A: Cabozantinib+ Best supportive care (BSC)'], 'description': 'Participants will receive BSC. BSC includes antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. but does not include tumor specific therapy.', 'name': 'Best Supportive Care (BSC)', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Arm B: Best supportive care (BSC)'], 'description': 'Participants will receive BSC alone. BSC includes antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. but does not include tumor specific therapy.', 'name': 'Best Supportive Care (BSC)', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.